Zalfermin Combo Missed Its Endpoint

A completed phase 2 trial found that adding zalfermin to semaglutide did not significantly improve the primary liver-fibrosis endpoint compared with placebo at 52 weeks. The result applies to the trial's combined population with stage F2 or F3 fibrosis and compensated F4 cirrhosis. It does not show that the combination worked in either cohort separately. Semaglutide alone produced a nominally significant result, but that pooled finding should not be recast as proof for people with cirrhosis.^[1]

The paper reports results from a randomized, double-blind, dose-ranging study, not a protocol or conference abstract. Investigators enrolled 698 adults at 187 sites and compared seven active or placebo groups. Novo Nordisk funded the study.^[1] The completed registry confirms the parallel design, quadruple masking and final enrolment count.^[2]

What the trial tested

Eligible participants had biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages F2, F3 or F4. The F4 group had compensated cirrhosis, meaning advanced scarring without the decompensating events that mark later liver failure. The registry excluded people with a history of clinically important ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis or liver transplantation. It also excluded participants with F4 disease who had grade 2 or worse gastro-oesophageal varices.^[2]

Participants were assigned to one of three zalfermin doses co-administered with semaglutide 2.4 mg, zalfermin 30 mg alone, semaglutide 2.4 mg alone, cagrilintide 2.4 mg with semaglutide 2.4 mg, or placebo. All regimens were given once weekly for 52 weeks. Those doses describe the research arms. They are not instructions for treatment, and zalfermin remains an investigational FGF21 analogue.^[1]

The primary endpoint required at least a one-stage improvement on the NASH Clinical Research Network fibrosis scale with no worsening of MASH at week 52.^[1] That is a biopsy-based surrogate outcome. The trial was not designed to show fewer episodes of liver decompensation, transplantation or death, and one year is too short to settle those longer clinical questions.

The combination missed the primary endpoint

The prespecified headline comparison was zalfermin 30 mg plus semaglutide 2.4 mg against placebo. Twenty-four of 99 participants in the combination arm met the primary endpoint, compared with 16 of 100 in the placebo arm. The estimated difference was 7.98 percentage points, with a 95% confidence interval from -3.82 to 19.79 and p=0.19.^[1] The interval includes no difference, so the trial did not establish added fibrosis benefit for the combination.

Semaglutide alone reached the endpoint in 30 of 100 participants. Its estimated difference from placebo was 14.05 percentage points (95% CI 1.88 to 26.23; p=0.024), which the authors call nominally significant.^[1] Nominal matters here: the result should not be treated as though it rescued the failed primary comparison or proved every subgroup benefited.

Zalfermin 30 mg alone produced a 22% response, compared with 16% on placebo, and the difference was not significant (p=0.39). The lower-dose zalfermin combinations and the exploratory cagrilintide plus semaglutide arm were not substantially different from placebo on the same endpoint.^[1] The abstract does not provide a stage-by-stage responder table, so it cannot support separate efficacy percentages for F2/F3 fibrosis and F4 cirrhosis.

Why fibrosis and cirrhosis cannot be merged

F2 and F3 describe significant fibrosis before cirrhosis. F4 marks cirrhosis, and this study limited that group to compensated disease. The biology, short-term risk and room for a one-stage biopsy change are not identical across those stages. Pooling them can answer the overall trial question, but it cannot tell a reader that a pooled response came from the F4 group.^[2]

The distinction is especially important because semaglutide has produced different findings in stage-specific trials. In the phase 3 ESSENCE interim analysis, which enrolled people with F2 or F3 fibrosis rather than cirrhosis, 36.8% on semaglutide and 22.4% on placebo had fibrosis improvement without worse steatohepatitis at week 72.^[3] A separate 71-person phase 2 study confined to compensated cirrhosis did not show a significant fibrosis benefit after 48 weeks: 11% responded on semaglutide and 29% on placebo (p=0.087).^[4]

Those earlier trials are context, not substitutes for a subgroup analysis of the new study. The new paper's conclusion that semaglutide merits further assessment in an F4 compensated-cirrhosis population is a research proposal. It is not a positive F4 efficacy result. Readers tracking the broader drug can use our semaglutide research overview to separate findings by indication and study design.

Safety needs the same careful reading

Adverse events were mostly non-serious and mild to moderate, but gastrointestinal events were common. They occurred in 80% of the 99 participants on zalfermin 30 mg plus semaglutide, 60% of 101 on zalfermin alone, 73% of 100 on semaglutide alone and 51% of 100 on placebo.^[1] The semaglutide safety section covers established GLP-1 adverse-effect context, but it should not be used to assign causality inside this multi-arm trial.

Serious adverse events occurred in 7% of the high-dose combination group, 13% with zalfermin 30 mg alone, 10% with semaglutide alone and 5% with placebo. Five deaths occurred across the study. Investigators assessed one death from heart failure in the zalfermin 30 mg group as possibly related to study drug.^[1] A single trial cannot define an uncommon safety rate, but that assessment belongs in any balanced account of the result.

What the result changes

The cleanest interpretation is narrow. Zalfermin did not add a statistically established fibrosis benefit to semaglutide on the trial's primary comparison. Semaglutide alone showed a signal in the combined F2-to-F4c population, while the accessible abstract leaves the stage-specific response unresolved. That makes a dedicated compensated-cirrhosis study more informative than another pooled claim.

This readout also does not change the need for clinical staging. A person with F2 fibrosis and a person with compensated F4 cirrhosis may share a MASH diagnosis while facing different surveillance and treatment decisions. Product approval and access also vary by jurisdiction; our semaglutide regulation overview tracks that question separately from investigational liver-disease evidence.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.